US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEUROGENE INC

12.86

+0.84006.99%

Volume:122.98K

Turnover:1.54M

Market Cap:183.41M

PE:-3.00

High:13.09

Open:12.31

Low:12.07

Close:12.02

Loading ...

Overview Company News Filings

Neurogene to Participate in Upcoming Conferences

Neurogene Insiders Placed Bullish Bets Worth US$1.46m

Simply Wall St.

Stifel Nicolaus Keeps Their Buy Rating on Neurogene (NGNE)

William Blair Reaffirms Their Buy Rating on Neurogene (NGNE)

Neurogene Price Target Maintained With a $55.00/Share by HC Wainwright & Co.

BRIEF-Neurogene Inc - Participant In Neurogene's Phase 1/2 Trial For Rett Syndrome Dies

Neurogene Shares Shares Down 5.5% After the Bell Following Announcement That Trial Participant Died, FDA Allowing It to Proceed With Trial for Rett Syndrome

THOMSON REUTERS

Neurogene Inc - Participant in Neurogene's Phase 1/2 Trial for Rett Syndrome Dies

THOMSON REUTERS

Neurogene Inc. Faces Uncertainty with NGN-101 Program Amid FDA Challenges and Strategic Hurdles

Neurogene Price Target Maintained With a $55.00/Share by HC Wainwright & Co.

Neurogene Inc reports results for the quarter ended September 30 - Earnings Summary

Neurogene Q3 2024 GAAP EPS $(1.19) Beats $(1.22) Estimate

BRIEF-Neurogene Q3 Net Income USD -20.217 Million

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

THOMSON REUTERS

Neurogene Inc Q3 Shr View $-1.22 -- Lseg Ibes Data

THOMSON REUTERS

Neurogene Inc: Strong Cash Position Provides Runway Into Second Half of 2027

THOMSON REUTERS

Neurogene Q3 Net Income USD -20.217 Million

THOMSON REUTERS

Press Release: Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

Neurogene Shares Down 35.1% After Co to Stop Giving High Dose of Gene Therapy to Patients in Study as It Investigates Possible Side Effect

THOMSON REUTERS

Neurogene Shares Down 20.5% Premarket After Co to Stop Giving High Dose of Gene Therapy to Patients in Study as It Investigates Possible Side Effect

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NGNE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NGNE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGNE\",,,,,undefined,":{"symbol":"NGNE","market":"US","secType":"STK","nameCN":"NEUROGENE INC","latestPrice":12.86,"timestamp":1745345046118,"preClose":12.02,"halted":0,"volume":122976,"delay":0,"floatShares":4877966,"shares":14262066,"eps":-4.28,"marketStatus":"Trading","change":0.84,"latestTime":"04-22 14:05:35 EDT","open":12.31,"high":13.09,"low":12.07,"amount":1542021.643008,"amplitude":0.084859,"askPrice":12.87,"askSize":55,"bidPrice":12.77,"bidSize":40,"shortable":3,"etf":0,"ttmEps":-4.28,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745352000000},"marketStatusCode":2,"adr":0,"listingDate":1394168400000,"exchange":"NASDAQ","adjPreClose":12.02,"preHourTrading":{"tag":"盘前","latestPrice":12.25,"preClose":12.02,"latestTime":"08:00 EDT","volume":300,"amount":3675,"timestamp":1745323200728},"postHourTrading":{"tag":"盘后","latestPrice":11.42,"preClose":12.02,"latestTime":"17:33 EDT","volume":550,"amount":6544.96,"timestamp":1745271184616},"volumeRatio":0.908816,"impliedVol":1.1932,"impliedVolPercentile":0.8372},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGNE\",,,,,undefined,":{"symbol":"NGNE","floatShares":4877966,"roa":"-18.49%","roe":"-30.28%","lyrEps":-4.277545,"volumeRatio":0.908816,"shares":14262066,"dividePrice":0,"high":13.09,"amplitude":0.084859,"preClose":12.02,"low":12.07,"week52Low":6.875,"pbRate":"0.59","psRate":"198.28","week52High":74.49,"institutionHeld":0,"latestPrice":12.86,"committee":-0.157895,"eps":-4.28,"divideRate":0,"volume":122976,"delay":0,"ttmEps":-4.28,"open":12.31,"prevYearClose":22.86,"prevWeekClose":11.49,"prevMonthClose":11.71,"prevQuarterClose":11.71,"fiveDayClose":10.89,"twentyDayClose":13.96,"sixtyDayClose":15.06},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NGNE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2513725817","title":"Neurogene to Participate in Upcoming Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2513725817","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513725817?lang=en_us&edition=fundamental","pubTime":"2025-02-24 20:30","pubTimestamp":1740400200,"startTime":"0","endTime":"0","summary":"NEW YORK, February 24, 2025----Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences:. TD Cowen 45th Annual Health Care ConferenceFormat: Management will participate in a fireside chat and investor meetingsDate: Monday, March 3 at 9:50 a.m. ET. Leerink Global Healthcare ConferenceFormat: Management will participate in a fireside chat and investor meetingsDate: Monday, March 10 at 1:00 p.m. ET. Stifel Virtual CNS ForumFormat: Management will participate in a fireside chatDate: Wednesday, March 19 at 9:30 a.m. ET. Live webcasts of the fireside chats will be accessible from the Investor Relations section of Neurogene’s website under events, where a replay of the events will also be available for a limited time.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurogene-participate-upcoming-conferences-123000601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2511031671","title":"Neurogene Insiders Placed Bullish Bets Worth US$1.46m","url":"https://stock-news.laohu8.com/highlight/detail?id=2511031671","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511031671?lang=en_us&edition=fundamental","pubTime":"2025-02-15 20:45","pubTimestamp":1739623502,"startTime":"0","endTime":"0","summary":"Quite a few insiders have dramatically grown their holdings in Neurogene Inc.  over the past 12 months. An insider's optimism about the company's prospects is a positive sign.Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.The Last 12 Months Of Insider Transactions At Neurogene. The recent insider purchases are heartening. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. Given that insiders also own a fair bit of Neurogene we think they are probably pretty confident of a bright future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurogene-insiders-placed-bullish-bets-124502893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2510851137","title":"Stifel Nicolaus Keeps Their Buy Rating on Neurogene (NGNE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510851137","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510851137?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:45","pubTimestamp":1739191551,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Neurogene (NGNE – Research Report) today and set a price target of $46.00. The comp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-neurogene-ngne-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-neurogene-ngne-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE","SF"],"gpt_icon":0},{"id":"2491361963","title":"William Blair Reaffirms Their Buy Rating on Neurogene (NGNE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491361963","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491361963?lang=en_us&edition=fundamental","pubTime":"2024-12-13 00:26","pubTimestamp":1734020769,"startTime":"0","endTime":"0","summary":"In a report released today, Sami Corwin from William Blair maintained a Buy rating on Neurogene (NGNE – Research Report). The company’s shares open...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/william-blair-reaffirms-their-buy-rating-on-neurogene-ngne?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/william-blair-reaffirms-their-buy-rating-on-neurogene-ngne?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE"],"gpt_icon":0},{"id":"2486085643","title":"Neurogene Price Target Maintained With a $55.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2486085643","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486085643?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:33","pubTimestamp":1732537980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NGNE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2024 07:33 ET (12:33 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE"],"gpt_icon":0},{"id":"2485423690","title":"BRIEF-Neurogene Inc - Participant In Neurogene's Phase 1/2 Trial For Rett Syndrome Dies","url":"https://stock-news.laohu8.com/highlight/detail?id=2485423690","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485423690?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:15","pubTimestamp":1732223714,"startTime":"0","endTime":"0","summary":"BRIEF-Neurogene Inc - Participant In Neurogene's Phase 1/2 Trial For Rett Syndrome DiesNov 21  - Neurogene Inc NGNE.O:NEUROGENE INC - PARTICIPANT IN NEUROGENE'S PHASE 1/2 TRIAL FOR RETT SYNDROME DIESNEUROGENE INC - FDA ALLOWS NEUROGENE TO PROCEED WITH PHASE 1/2 TRIAL USING 1E15 VG DOSESource text: [t.ly/aIzVh]Further company coverage: NGNE.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MS13T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2485642335","title":"Neurogene Shares Shares Down 5.5% After the Bell Following Announcement That Trial Participant Died, FDA Allowing It to Proceed With Trial for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2485642335","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485642335?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:12","pubTimestamp":1732223549,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nL1N3MS14O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2485466428","title":"Neurogene Inc - Participant in Neurogene's Phase 1/2 Trial for Rett Syndrome Dies","url":"https://stock-news.laohu8.com/highlight/detail?id=2485466428","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485466428?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:05","pubTimestamp":1732223100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MS13T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2484287156","title":"Neurogene Inc. Faces Uncertainty with NGN-101 Program Amid FDA Challenges and Strategic Hurdles","url":"https://stock-news.laohu8.com/highlight/detail?id=2484287156","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484287156?lang=en_us&edition=fundamental","pubTime":"2024-11-20 14:00","pubTimestamp":1732082405,"startTime":"0","endTime":"0","summary":"Neurogene Inc. (NGNE) has disclosed a new risk, in the Corporate Activity and Growth category. Neurogene Inc. faces a significant business risk wit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurogene-inc-faces-uncertainty-with-ngn-101-program-amid-fda-challenges-and-strategic-hurdles?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurogene-inc-faces-uncertainty-with-ngn-101-program-amid-fda-challenges-and-strategic-hurdles?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2484910538","title":"Neurogene Price Target Maintained With a $55.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2484910538","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484910538?lang=en_us&edition=fundamental","pubTime":"2024-11-19 19:52","pubTimestamp":1732017120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NGNE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2024 06:52 ET (11:52 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE"],"gpt_icon":0},{"id":"2484933561","title":"Neurogene Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2484933561","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484933561?lang=en_us&edition=fundamental","pubTime":"2024-11-19 07:08","pubTimestamp":1731971287,"startTime":"0","endTime":"0","summary":"Neurogene Inc reports results for the quarter ended September 30 - Earnings SummaryNeurogene Inc NGNE.OQ reported a quarterly adjusted loss of $1.19 per share for the quarter ended September 30, highe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL8N3MP1XP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE"],"gpt_icon":0},{"id":"2484987040","title":"Neurogene Q3 2024 GAAP EPS $(1.19) Beats $(1.22) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2484987040","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484987040?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:26","pubTimestamp":1731968785,"startTime":"0","endTime":"0","summary":"Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.19) per share which beat the analyst consensus estimate of $(1.22) by 2.46 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/42050627/neurogene-q3-2024-gaap-eps-1-19-beats-1-22-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Neurogene Q3 2024 GAAP EPS $(1.19) Beats $(1.22) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE"],"gpt_icon":0},{"id":"2484987053","title":"BRIEF-Neurogene Q3 Net Income USD -20.217 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2484987053","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484987053?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:25","pubTimestamp":1731968745,"startTime":"0","endTime":"0","summary":"BRIEF-Neurogene Q3 Net Income USD -20.217 Million\n\n\nNov 18 (Reuters) - Neurogene Q3 operating expenses USD 22.18 million.\n\nQ3 operating income USD -22.18 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nPLX01796F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2484987702","title":"Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2484987702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484987702?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:25","pubTimestamp":1731968700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUA9CCKWY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2484870169","title":"Neurogene Inc  Q3 Shr View $-1.22 -- Lseg Ibes Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2484870169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484870169?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:25","pubTimestamp":1731968700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUA9CCKWY:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2484698705","title":"Neurogene Inc: Strong Cash Position Provides Runway Into Second Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2484698705","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484698705?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:25","pubTimestamp":1731968700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUA9CCKWY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2484877729","title":"Neurogene Q3 Net Income USD -20.217 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2484877729","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484877729?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:25","pubTimestamp":1731968700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nPLX01796F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2484870999","title":"Press Release: Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2484870999","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484870999?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:25","pubTimestamp":1731968700,"startTime":"0","endTime":"0","summary":"Announced positive interim clinical data with 1E15 vg dose of NGN-401 gene therapy trial for Rett syndrome. Expects to provide an update on registrational trial design in first half of 2025. Strong cash position provides runway into the second half of 2027. Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter 2024 financial results and highlighted recent corporate updates.Third Quarter 2024 and Recent Highlights, and Anticipated Milestones. Phase 1/2 Trial of NGN-401 Gene Therapy for Treatment of Rett Syndrome. NGN-401 is currently being evaluated in an ongoing, open-label Phase 1/2 trial. Key updates include:. Announced today an update to the NGN-401 clinical trial. Following a treatment-related serious adverse event  in the. third participant dosed with 3E15 vg, Neurogene paused further use. of the 3E15 vg dose and does not plan to enroll any further. T","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2484675902","title":"Neurogene Shares Down 35.1% After Co to Stop Giving High Dose of Gene Therapy to Patients in Study as It Investigates Possible Side Effect","url":"https://stock-news.laohu8.com/highlight/detail?id=2484675902","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484675902?lang=en_us&edition=fundamental","pubTime":"2024-11-18 22:32","pubTimestamp":1731940371,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nFWN3MP196:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2484621004","title":"Neurogene Shares Down 20.5% Premarket After Co to Stop Giving High Dose of Gene Therapy to Patients in Study as It Investigates Possible Side Effect","url":"https://stock-news.laohu8.com/highlight/detail?id=2484621004","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484621004?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:47","pubTimestamp":1731934020,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nFWN3MP0V0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":79,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NGNE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-24","symbol":"NGNE","fiscalQuarterEnding":"2024/12","expectedEps":-1.04,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":-0.99},{"market":"US","date":"2024-11-18","symbol":"NGNE","fiscalQuarterEnding":"2024/09","expectedEps":-1.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731906000000,"reportTimeType":"post","actualEps":-1.19},{"market":"US","date":"2024-08-09","symbol":"NGNE","fiscalQuarterEnding":"2024/06","expectedEps":-1.02,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"pre","actualEps":-1.09},{"market":"US","date":"2024-05-10","symbol":"NGNE","fiscalQuarterEnding":"2024/03","expectedEps":-1.03,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715313600000,"reportTimeType":"pre","actualEps":1},{"market":"US","date":"2024-03-18","symbol":"NGNE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1710734400000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NGNE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NGNE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5714,"buy":0.4286,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5714,"analysts":7,"updateTime":1719633600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NGNE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NGNE","date":"2025-04-21","current":-2.180761,"percent":0.967638,"low":-19.523035,"twenty":-11.997304,"median":-9.278423,"eighty":-4.955201,"high":-1.458307,"avg":-8.934384,"sd":3.869233,"marketCap":163871138},"quantilePoints":[{"date":"2023-12-29","current":-4.323556,"twenty":-4.185645,"median":-3.978778,"eighty":-3.916869,"marketCap":220311097},{"date":"2024-01-05","current":-5.423319,"twenty":-5.000527,"median":-4.624292,"eighty":-3.978778,"marketCap":276350648},{"date":"2024-01-12","current":-8.005373,"twenty":-7.157271,"median":-5.423319,"eighty":-4.323556,"marketCap":407921769},{"date":"2024-01-19","current":-7.59768,"twenty":-7.599292,"median":-7.086806,"eighty":-4.804734,"marketCap":387147382},{"date":"2024-01-26","current":-8.053188,"twenty":-7.611677,"median":-7.561189,"eighty":-4.985427,"marketCap":410358272},{"date":"2024-02-02","current":-7.741127,"twenty":-7.937424,"median":-7.577547,"eighty":-5.338761,"marketCap":394456888},{"date":"2024-02-09","current":-7.497015,"twenty":-7.980207,"median":-7.59013,"eighty":-6.388695,"marketCap":382017903},{"date":"2024-02-16","current":-7.549864,"twenty":-7.937424,"median":-7.577547,"eighty":-6.995453,"marketCap":384710880},{"date":"2024-02-23","current":-7.622846,"twenty":-7.894138,"median":-7.57503,"eighty":-7.129085,"marketCap":388429751},{"date":"2024-03-01","current":-7.819143,"twenty":-7.894138,"median":-7.588872,"eighty":-7.262969,"marketCap":398432234},{"date":"2024-03-08","current":-9.734292,"twenty":-8.024499,"median":-7.59768,"eighty":-7.381754,"marketCap":496020561},{"date":"2024-03-15","current":-8.697444,"twenty":-8.083388,"median":-7.629138,"eighty":-7.463796,"marketCap":443186933},{"date":"2024-03-22","current":-17.419498,"twenty":-9.10262,"median":-7.660596,"eighty":-7.498525,"marketCap":632623921},{"date":"2024-03-28","current":-17.433655,"twenty":-9.373408,"median":-7.741127,"eighty":-7.499532,"marketCap":633138041},{"date":"2024-04-05","current":-15.090764,"twenty":-9.721205,"median":-7.845567,"eighty":-7.510605,"marketCap":548051280},{"date":"2024-04-12","current":-13.565408,"twenty":-14.180505,"median":-7.97769,"eighty":-7.536275,"marketCap":492654915},{"date":"2024-04-19","current":-11.176509,"twenty":-13.912948,"median":-8.029281,"eighty":-7.549864,"marketCap":405897266},{"date":"2024-04-26","current":-10.571321,"twenty":-13.650346,"median":-8.053188,"eighty":-7.549864,"marketCap":383918661},{"date":"2024-05-03","current":-12.537284,"twenty":-13.442874,"median":-8.146303,"eighty":-7.558924,"marketCap":455316556},{"date":"2024-05-10","current":-11.764996,"twenty":-13.2542,"median":-9.074937,"eighty":-7.57352,"marketCap":427269365},{"date":"2024-05-17","current":-10.587696,"twenty":-13.13876,"median":-9.272492,"eighty":-7.576037,"marketCap":433830864},{"date":"2024-05-24","current":-9.887502,"twenty":-12.800854,"median":-9.44488,"eighty":-7.581574,"marketCap":405140389},{"date":"2024-05-31","current":-10.685033,"twenty":-12.52136,"median":-9.620612,"eighty":-7.588117,"marketCap":437819226},{"date":"2024-06-07","current":-11.771752,"twenty":-12.409114,"median":-9.810897,"eighty":-7.59013,"marketCap":482347539},{"date":"2024-06-14","current":-13.301826,"twenty":-12.457666,"median":-9.93146,"eighty":-7.59013,"marketCap":545042335},{"date":"2024-06-21","current":-9.842528,"twenty":-12.564112,"median":-9.93146,"eighty":-7.59617,"marketCap":403297579},{"date":"2024-06-28","current":-11.030474,"twenty":-12.52136,"median":-10.019377,"eighty":-7.599292,"marketCap":451973662},{"date":"2024-07-05","current":-11.397945,"twenty":-12.537284,"median":-10.188931,"eighty":-7.605739,"marketCap":467030798},{"date":"2024-07-12","current":-13.232134,"twenty":-12.537284,"median":-10.458961,"eighty":-7.622846,"marketCap":542186671},{"date":"2024-07-15","current":-13.48873,"twenty":-12.644595,"median":-10.463671,"eighty":-7.625363,"marketCap":552700705},{"date":"2024-08-02","current":-12.832984,"twenty":-12.76836,"median":-10.468381,"eighty":-7.627879,"marketCap":525831507},{"date":"2024-08-09","current":-11.578513,"twenty":-12.617767,"median":-10.579508,"eighty":-7.644992,"marketCap":474429562},{"date":"2024-08-16","current":-9.721942,"twenty":-12.533918,"median":-10.468381,"eighty":-7.659841,"marketCap":462832495},{"date":"2024-08-23","current":-9.22793,"twenty":-12.500388,"median":-10.20777,"eighty":-7.686769,"marketCap":439314055},{"date":"2024-08-30","current":-9.934831,"twenty":-12.3607,"median":-10.082175,"eighty":-7.732068,"marketCap":472967513},{"date":"2024-09-06","current":-9.383503,"twenty":-12.215183,"median":-10.030358,"eighty":-7.751697,"marketCap":446720414},{"date":"2024-09-13","current":-11.015654,"twenty":-12.198503,"median":-10.056266,"eighty":-7.799009,"marketCap":524422220},{"date":"2024-09-20","current":-11.343175,"twenty":-12.111032,"median":-10.20463,"eighty":-7.829713,"marketCap":540014556},{"date":"2024-09-27","current":-10.69359,"twenty":-12.018852,"median":-10.282823,"eighty":-7.883065,"marketCap":509089757},{"date":"2024-10-04","current":-12.12104,"twenty":-12.018852,"median":-10.468381,"eighty":-7.937424,"marketCap":577046353},{"date":"2024-10-11","current":-13.141817,"twenty":-12.215183,"median":-10.579508,"eighty":-7.980207,"marketCap":625642465},{"date":"2024-10-18","current":-14.443716,"twenty":-12.644595,"median":-10.678753,"eighty":-7.993293,"marketCap":687621999},{"date":"2024-10-25","current":-13.155463,"twenty":-12.975228,"median":-10.69616,"eighty":-8.014936,"marketCap":626292146},{"date":"2024-10-31","current":-11.938174,"twenty":-12.976568,"median":-10.764003,"eighty":-8.053188,"marketCap":568340632},{"date":"2024-11-08","current":-18.968977,"twenty":-13.201862,"median":-10.833215,"eighty":-8.053188,"marketCap":903056103},{"date":"2024-11-15","current":-10.699049,"twenty":-13.232134,"median":-10.867118,"eighty":-8.053188,"marketCap":509349629},{"date":"2024-11-22","current":-3.804354,"twenty":-13.201862,"median":-10.811892,"eighty":-8.005373,"marketCap":202570426},{"date":"2024-11-29","current":-7.081932,"twenty":-13.164743,"median":-10.73726,"eighty":-7.916284,"marketCap":377091628},{"date":"2024-12-06","current":-6.123936,"twenty":-13.144546,"median":-10.69616,"eighty":-7.738107,"marketCap":326081199},{"date":"2024-12-13","current":-6.220014,"twenty":-13.009618,"median":-10.678753,"eighty":-7.632912,"marketCap":331197071},{"date":"2024-12-20","current":-6.147607,"twenty":-12.971208,"median":-10.579508,"eighty":-7.59013,"marketCap":327341631},{"date":"2024-12-27","current":-6.711544,"twenty":-12.908645,"median":-10.50763,"eighty":-7.57654,"marketCap":357369573},{"date":"2025-01-03","current":-6.374574,"twenty":-12.853892,"median":-10.405691,"eighty":-7.549864,"marketCap":339426951},{"date":"2025-01-10","current":-5.995231,"twenty":-12.800672,"median":-10.212067,"eighty":-7.505069,"marketCap":319228040},{"date":"2025-01-17","current":-4.918377,"twenty":-12.651961,"median":-10.173232,"eighty":-7.427764,"marketCap":261888801},{"date":"2025-01-24","current":-4.346472,"twenty":-12.574112,"median":-10.030358,"eighty":-7.086806,"marketCap":231436615},{"date":"2025-01-31","current":-4.332524,"twenty":-12.537284,"median":-9.920586,"eighty":-6.842433,"marketCap":230693879},{"date":"2025-02-07","current":-6.50018,"twenty":-12.535901,"median":-9.842528,"eighty":-6.605719,"marketCap":346115092},{"date":"2025-02-14","current":-5.236411,"twenty":-12.52887,"median":-9.777894,"eighty":-6.491539,"marketCap":278823188},{"date":"2025-02-21","current":-4.829104,"twenty":-12.471907,"median":-9.750601,"eighty":-6.430271,"marketCap":257135289},{"date":"2025-02-28","current":-4.770518,"twenty":-12.349943,"median":-9.721942,"eighty":-6.303838,"marketCap":254015797},{"date":"2025-03-07","current":-4.672876,"twenty":-12.236804,"median":-9.661093,"eighty":-6.2189,"marketCap":248816643},{"date":"2025-03-14","current":-4.686825,"twenty":-12.214976,"median":-9.588204,"eighty":-6.130619,"marketCap":249559380},{"date":"2025-03-21","current":-4.24883,"twenty":-12.149292,"median":-9.555425,"eighty":-6.004158,"marketCap":226237461},{"date":"2025-03-28","current":-3.045755,"twenty":-12.12341,"median":-9.468113,"eighty":-5.45457,"marketCap":228870246},{"date":"2025-04-04","current":-1.92123,"twenty":-12.043093,"median":-9.418302,"eighty":-5.225252,"marketCap":144368903},{"date":"2025-04-11","current":-1.782154,"twenty":-12.004592,"median":-9.374415,"eighty":-5.034123,"marketCap":133918207},{"date":"2025-04-17","current":-2.044108,"twenty":-11.997937,"median":-9.328916,"eighty":-4.961897,"marketCap":153602450},{"date":"2025-04-21","current":-2.180761,"twenty":-11.997304,"median":-9.278423,"eighty":-4.955201,"marketCap":163871138}],"updateTime":1745344221421}}}